Authors and Disclosures
Luca Liberale, MD, PHDa,b, Lina Badimon, PHDc, Fabrizio Montecucco, MD, PHDb,d, Thomas F. Lüscher, MDa,e, Peter Libby, MDf and Giovanni G. Camici, PHDa,g,h
aCenter for Molecular Cardiology, University of Zurich, Schlieren, Switzerland; bFirst Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, Genoa, Italy; cCardiovascular Research Program ICCC, IR-IIB Sant Pau, Hospital de la Santa Creu i Sant Pau, CiberCV–Institute Carlos III, Barcelona, Spain; dIRCCS Ospedale Policlinico San Martino Genoa–Italian Cardiovascular Network, Genoa, Italy; eRoyal Brompton and Harefield Hospitals and Imperial College, London, United Kingdom; fDivision of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA; gUniversity Heart Center, Department of Cardiology, University Hospital Zurich, Zurich, Switzerland; and the hDepartment of Research and Education, University Hospital Zurich, Zurich, Switzerland.
Address for Correspondence
Dr Giovanni G. Camici, Center for Molecular Cardiology, University of Zurich, Wagistrasse 12, Schlieren CH-8952, Switzerland. E-mail: giovanni.camici@uzh.ch. Twitter: @cmc_uzh, @UniGenova, @liberale_luca, @lbadimon, @TomLuscher.
The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors' institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the Author Center.
Funding Support and Author Disclosures
Dr Camici has received support for this work from the Swiss National Science Foundation (310030_175546), the Swiss Heart Foundation, Alfred and Annemarie von Sick Grants for Translational and Clinical Research Cardiology and Oncology, and the Foundation for Cardiovascular Research–Zurich Heart House; and is the recipient of a Sheikh Khalifa's Foundation Assistant Professorship at the Faculty of Medicine, University of Zurich. Dr Liberale has received support from the Swiss Heart Foundation and the Novartis Foundation for Medical-Biological Research. Dr Libby has received funding support from the National Heart, Lung, and Blood Institute (1R01HL134892), the American Heart Association (18CSA34080399), the RRM Charitable Fund, and the Simard Fund. Dr Montecucco has received support from the "Rete Cardiologica" of Italian Ministry of Health (#2754291). Drs Liberale, Libby, and Camici are coinventors on the International Patent WO/2020/226993 filed in April 2020; the patent relates to the use of antibodies which specifically bind interleukin-1α to reduce various sequelae of ischemia-reperfusion injury to the central nervous system. Dr Liberale has received speaker fees outside of this work from Daichi-Sankyo. Dr Badimon is founder of 2 spin-offs (Glycardial Diagnostics and Ivestatin Therapeutics); has several patents; has received consultancy fees from Sanofi and Novartis; and has received speaker fees from Lilly, Pfizer, and AstraZeneca (all unrelated to this work). Dr Lüscher has received educational and research grants outside this work from Abbott, Amgen, AstraZeneca, Boehringer Ingelheim, Daichi-Sankyo, Novartis, Servier, Sanofi, and Vifor; and has received speaker fees from Amgen and Daiichi-Sankyo. Dr Libby has served as an unpaid consultant to or been involved in clinical trials for Amgen, AstraZeneca, Baim Institute, Beren Therapeutics, Esperion Therapeutics, Genentech, Kancera, Kowa Pharmaceuticals, Medimmune, Merck, Norvo Nordisk, Novartis, Pfizer, and Sanofi-Regeneron; has served as a member of scientific advisory board for Amgen, Caristo, Cartesian, Corvidia Therapeutics, CSL Behring, DalCor Pharmaceuticals, Dewpoint, Kowa Pharmaceuticals, Olatec Therapeutics, Medimmune, Novartis, PlaqueTec, and XBiotech; his laboratory has received research funding in the last 2 years from Novartis; has served on the Board of Directors of XBiotech, Inc; has a financial interest in XBiotech, a company developing therapeutic human antibodies; and his interests were reviewed and are managed by Brigham and Women's Hospital and Partners HealthCare in accordance with their conflict-of-interest policies. Dr Montecucco has reported that he has no relationships relevant to the contents of this paper to disclose.
